circulating immune cell subsets in patients with melanoma from the opacin-neo trial
Published 1 year ago • 47 plays • Length 0:57Download video MP4
Download video MP3
Similar videos
-
1:39
opacin and opacin-neo: neoadjuvant immunotherapy for advanced melanoma
-
2:52
opacin-neo trial rfs and biomarker analyses: optimal neoadjuvant ipi/nivo dosing in melanoma
-
2:43
tumor characteristics of patients with recurrence after neoadjuvant ipi nivo in melanoma
-
3:09
advances in utilizing neoadjuvant immunotherapy in melanoma
-
3:35
keynote-006: the efficacy of ipilimumab after pembrolizumab in patients with advanced melanoma
-
1:16
neoadjuvant ipi nivo in stage iii melanoma: updates from opacin & opacin-neo
-
2:53
opacin-neo: tmb and ifn-γ identified as biomarkers of pathologic response in melanoma
-
2:22
adjuvant nivolumab in patents with high-risk resected melanoma
-
1:12
investigators present updated results of the opacin trial for melanoma
-
2:54
combining nivolumab and ipilimumab in patients with resected stage iv melanoma
-
10:42
what is new in melanoma?
-
3:15
optimal neoadjuvant io in resectable stage iii melanoma: interferon gamma signature analysis
-
3:03
what's the best option in the treatment of melanoma?
-
1:12
current trials in the treatment of melanoma
-
1:48
influence of new immunotherapy checkpoint inhibitors in melanoma
-
0:51
what role will tils play in treating patients with melanoma?
-
1:25
results of checkmate 039 trial of nivolumab in combination with ipilimumab for hodgkin lymphoma
-
0:47
enhancing responses to immunotherapy in melanoma via the gut microbiota
-
5:44
4-year results from checkmate 238: adjuvant nivo vs ipi in resected stage iii/iv melanoma